Zobrazeno 1 - 10
of 78
pro vyhledávání: '"милдронат"'
Autor:
I. V. Sergienko, V. V. Kukharchuk, S. A. Gabrusenko, V. V. Malakhov, V. P. Masenko, M. I. Tripoten, T. V. Balahonova
Publikováno v:
Рациональная фармакотерапия в кардиологии, Vol 3, Iss 3, Pp 10-14 (2015)
Aim. To study the effect of treatment with metabolic corrector mildronate on lipid profile, inflammatory factors and endothelium function in patients with ischemic heart disease (IHD).Material and methods. 60 patients with IHD (stable exertional angi
Externí odkaz:
https://doaj.org/article/9d736cc9078b498ba537d66ebeafdc23
Autor:
N. P. Kutishenko, N. A. Dmitrieva, Y. V. Lukina, M. P. Kozireva, Y. E. Semyonova, A. D. Deev, S. Y. Martsevich
Publikováno v:
Рациональная фармакотерапия в кардиологии, Vol 1, Iss 2, Pp 37-42 (2015)
Aim. To study influence of mildronate (M) on treatment efficiency of patients with ischemic heart disease (IHD), receiving standard antianginal therapy (AAT)Materials and methods. Double-blind, randomized, placebo-controlled study was carried out in
Externí odkaz:
https://doaj.org/article/fecfb98b9aef468eb6fa669ebd156a00
Publikováno v:
Архивъ внутренней медицины, Vol 0, Iss 5, Pp 40-44 (2015)
A randomized study of the state of stiffness parameters arteries wall (CAVI — cardio-ankle vascular index), AI (augmentation index) PEP (duration of the voltage of the left ventricle) using «VaSera-1000» («Fukuda Denshi», Japan) in primary hype
Externí odkaz:
https://doaj.org/article/2ef46dfa165c409cb69894db1694c260
Publikováno v:
Кардиоваскулярная терапия и профилактика, Vol 13, Iss 1, Pp 27-32 (2014)
Aim. To assess the effectiveness of Mildronate in the prevention of arrhythmias during the perioperative period of open cholecystectomy under intravenous multicomponent anesthesia.Material and methods. In total, 69 patients were divided into 3 groups
Externí odkaz:
https://doaj.org/article/c06b9e91416d4d99ade15f007958dd76
Autor:
I. Ya. Kalvinsh
Publikováno v:
Кардиоваскулярная терапия и профилактика, Vol 12, Iss 5, Pp 87-90 (2013)
It has been demonstrated that one of the factors in the pathogenesis of atherosclerosis, with the subsequent development of myocardial infarction (MI), stroke (S), or sudden death (SD), is trimethylaminoxide (TMAO), the end-product of dietary choline
Externí odkaz:
https://doaj.org/article/553c193b584c4cdea241698eaca6d737
В статье анализируется уровень восстановленного глутатиона в тканях крыс при введении Милдроната и сукцината хитозана животным с эксп
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b918f5f2d7e7d8235a8f30a984835843
Лечение основных проявлений астенического синдрома (АС) является актуальной задачей в клинической практике врачей первичного звена. Бы
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::48b40c8ffd24750f1fe316920ca9c3e3
Autor:
А. Л. Вёрткин, Н. О. Ховасова
Publikováno v:
Архивъ внутренней медицины, Vol 0, Iss 4, Pp 68-72 (2013)
Risk factors are triggers that lead to oxidative stress, endothelial dysfunction, initiation of apoptosis and energy deficit. This universal mechanism of injury leads to polysystemic defeat and development of comorbide disease. Use of metabolic corre
Externí odkaz:
https://doaj.org/article/52a5ede343904de0a7ed3630ffd9d9a5
Publikováno v:
Кардиоваскулярная терапия и профилактика, Vol 12, Iss 2, Pp 94-97 (2013)
The paper is focused on hypoxia and cell ischemia as universal pathogenetic mechanisms of disease development, which can be addressed by both etiotropic and pathogenetic therapy. The latter is represented by the so-called metabolic correctors. At pre
Externí odkaz:
https://doaj.org/article/9908d2bcbd1c4123891f518683ded9b6
Autor:
S. V. Nedogoda, M. E. Statsenko, S. V. Turkina, I. A. Tyshchenko, L. V. Poletaeva, V. V. Tsoma, A. A. Ledyaeva, E. N. Chumachok, O. L. Bykova
Publikováno v:
Кардиоваскулярная терапия и профилактика, Vol 11, Iss 5, Pp 33-38 (2012)
Aim. To assess the effects of the “interval” (3 months of treatment, followed by treatment-free 3 months) and “persistent” (52 weeks) therapy with Mildronate (500 mg/d) in elderly patients with arterial hypertension (AH) and cognitive dysfunc
Externí odkaz:
https://doaj.org/article/86c9d26773424015b07f1f669659fc7b